A Study to Evaluate Safety and Dosimetry of [18F]4-FDF, a New PET Imaging Agent for Inflammation

Inclusion Criteria: 1. Male or female, ages 18-55 years inclusively at time of consent 2. Body Mass Index (BMI) of 18 to 30 kg/m2, inclusively 3. Capable of providing informed consent 4. Able to speak and read in English or French 5. Able to comply with all study procedures (including fasting for 12 hours, lying still in a supine position for about 90 minutes) Exclusion Criteria: 1. Known hypersensitivity NeuCaVis or its excipients 2. Blood glucose level higher than 200mg/dl at screening 3. Active viral infection at screening 4. Currently taking anti-inflammatory medications (e.g. ASA, NSAIDs, corticosteroids, immunomodulating agents, colchicine) 5. Any anatomical heart abnormality, or cardiovascular condition including acute cardiac condition, suspicion of cardiac inflammation, and/or coronary artery disease, that may confound the analysis of the data based on the investigator's clinical opinion. 6. Recent (in the past 6 months) history of head trauma 7. Abnormal and clinically significant results on the physical examination, vital signs, or laboratory tests at screening. 8. Clinically significant neurologic, neurodevelopmental, cardiovascular, renal, hepatic, hematological, gastrointestinal, pulmonary, or metabolic-endocrine disorder 9. Female participants who are pregnant, planning to become pregnant during the study or breastfeeding 10. If of childbearing potential, unwilling or unable to use of a highly effective method of contraception as outlined in the protocol for the duration of the study. 11. Any contraindication to PET or CT imaging. 12. Actively participating in other interventional clinical trial(s). 13. Unwilling to comply with study procedures, medication restrictions or attend all study visits 14. Any other condition that, in the opinion of the investigator, could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results.